Enacts provisions relating to insurance coverage for prescription insulin drugs

SB 175 proposes changes to how insurance companies cover prescription insulin drugs. The bill directly affects patients who rely on insulin for diabetes management and the insurance providers who administer these plans. It would establish specific requirements for insurance coverage of insulin medications, though the exact details of these requirements are not yet specified in the available information. The legislation is currently in the early stages of review by the Senate Insurance and Banking Committee.